Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid ...

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

In that spirit, let's consider two biotech companies that could potentially deliver incredible returns next year: Recursion Pharmaceuticals (NASDAQ: RXRX) and BioAge Labs (NASDAQ: BIOA). Are these ...

Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...

Democrat Wesley Harris and Republican Brad Briner are vying to be the state’s next treasurer, overseeing the management of ...

Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

The logic suggested by the Lilly trial is the opposite, however. It proposes that being overweight is a primary cause of ...

The Center for Human Nutrition at the U of A is conducting a research study to learn more about the effects of protein on body composition and wellbeing in people getting ready to take weight loss ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...